Abstract:Background: Diffuse large B cell lymphomas (DLBCLs) are aggressive tumors that account for almost half of all lymphoma incidences. In particular, double-hit and triple-hit DLBCLs, with translocations involving BCL2, MYC and/or BCL6, have a very poor prognosis and occur in up to 7% of cases. Double expressor DLBCLs, with overexpression of BCL2 and MYC in the absence of chromosomal translocations, also have a poor prognosis. BCL2 inhibitors (BCL2i) have shown preclinical and clinical efficacy in lymphomas. Here, we synthesized and tested seven novel BCL2i in DLBCL cells with deregulated BCL2, and splenic marginal zone lymphoma (SMZL) cell lines with acquired resistance to idelalisib, copanlisib or ibrutinib. Methods: Using in silico-based drug design complemented by classical and kinetic target-guided synthesis (KTGS) led to the synthesis of seven potential BCL2 inhibitors (BCL2i). The MTT assay was used to assess the anti-proliferative activities of BCL2i: ST-59, ST-64, ST-65, R, Z-89, Z-103, Z-116-8 in BCL2-translocated DLBCLs: SU-DHL-4, Toledo, DOHH2, KARPAS422, WSUDLCL2, Pfeiffer; BCL2 amplified DLBCL: U2932 and resistant SMZLs. Cells were treated with increasing concentrations of BCL2i for 72 hours [h]. Results: Median IC50 values for the seven BCL2i ranged from 22 μM to 49 μM. ST-65 was the most potent BCL2i (range = 12 - 46 μM, median = 22 μM), showing anti-proliferative activity in DLBCL and SMZL. The other BCL2i were inactive in at least 2 cell lines (IC50 > 50 μM). The three least potent BCL2i were Z-89, Z-103 and R (median IC50 = 49, 44 and 45 μM, respectively). ST-65 was the only BCL2i synthesized by BCL2 using KTGS, indicating KTGS as a superior technique for generating BCL2i. The poor activity of R agreed with its inability to cross the cell membrane as determined by liquid chromatography-mass spectrometry. Among the resistant SMZLs, parental KARPAS1718 were most sensitive to the BCL2i, responding to 5 out of 7 inhibitors (range = 11 - 47 μM, median = 22 μM). The activated B cell like (ABC)-DLBCL, U2932, was only sensitive to ST-65 (IC50 = 20 μM). U2932 lacks translocated BCL2, but BCL2 is amplified and overexpressed in this cell line. Conclusions: We report the in vitro anti-lymphoma activities of novel BCL2i, particularly ST-65, in DLBCL and SMZL cells. Our results suggest that these compounds are structures further exploitable for the design of improved anti-lymphoma drugs. Acknowledgements: The research work was supported by the Hellenic Foundation for Research and Innovation (H.F.R.I.) under the "First Call for H.F.R.I. Research Projects to support Faculty members and Researchers and the procurement of high-cost research equipment grant" (Project Number: 991 to AGT). Citation Format: Afua Adjeiwaa Mensah, Christos M. Chatzigiannis, Dimitrios A. Diamantis, Vasileios K. Gkalpinos, Alberto Arribas, Andreas G. Tzakos, Francesco Bertoni. Novel BCL2 inhibitors with anti-lymphoma activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 3942.

Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors

Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.

Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays

Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders

Discovery and Structure-Activity Relationship of Novel Diphenylthiazole Derivatives As BTK Inhibitor with Potent Activity Against B Cell Lymphoma Cell Lines.

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Optimization of a Novel DEL Hit That Binds in the Cbl-b SH2 Domain and Blocks Substrate Binding

Structure-Based Optimization of a Series of Covalent, Cell Active Bfl-1 Inhibitors

Discovery and Development of Thiazolo[3,2-a]pyrimidinone Derivatives As General Inhibitors of Bcl-2 Family Proteins

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC to Provide Insight into Small Molecule Targeting of BCL6

Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.

Computational study on novel natural inhibitors targeting BCL2

Abstract 3942: Novel BCL2 inhibitors with anti-lymphoma activity

Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo

CC-122, a Pleiotropic Pathway Modifier, Mimics an Interferon Response and Has Antitumor Activity in DLBCL

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond

An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.

Synthesis and Biological Evaluation of Novel Aromatic-Heterocyclic Biphenyls As Potent Anti-Leukemia Agents

Discovery and Biological Evaluation of Pyrimido[4,5-D]pyrimidine-2,4(1h,3h)-dione Derivatives As Potent Bruton’s Tyrosine Kinase Inhibitors

GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice